Company profilePharmaceutical#390 of 1,318 in Pakistan✓ No DRAP alerts

SAAAF PHARMACEUTICALS

Pharmaceutical company · 43 brands · 41 molecules

Ranked #106 of 137 companies in Anti-Infectives

43 registered products 15 pharmaceutical brands 41 distinct molecules 0 DRAP alerts

Company overview

43
registered products
15
pharmaceutical brands
41
distinct molecules
1
therapeutic classes
0
DRAP alerts

SAAAF PHARMACEUTICALS is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 43 product registrations across 41 distinct molecules. Its portfolio is concentrated in Anti-Infectives. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by SAAAF

1 product matched in our catalogue — each with its observed price and DRAP approved ceiling.

Anti-Infectives 1

Top molecules by brand count

Diclofenac2 brands
Cefixime2 brands
Montelukast2 brands
Fluoxetine1 brand

Therapeutic classes

Anti-Infectives · 1

Conditions treated

General Infections · 1

Price band (DRAP official ceilings)

Registered products priced by source
Servaid1 products · Rs 369 – Rs 369
Median across source: Rs 369

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Wilshire Laboratories (Private) Limited holds 132 molecules not in this portfolio
AcyclovirAcyclovir SodiumAlfacalcidolAmlodipineAmoxicillinAmoxycillin
BIO LABS (PVT) LTD. holds 138 molecules not in this portfolio
000 I.UAmlodipineAprepitantAremetherArtemetherArtesunate
FYNK PHARMACEUTICALS holds 2 molecules not in this portfolio
BisoprololItopride

Get the full profile for SAAAF

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.